Maria Sara Remedi

Maria Sara Remedi

Auto-generated profile, based on publicly available information

Maria Sara Remedi

Department of Medicine Division of Endocrinology Metabolism and Lipid Research School of Medicine Washington University in St Louis St Louis Missouri USA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2014 in Cell Metabolism
Verified
Journal Article
Closed access
ZWZhiyu Wang
Zhiyu Wang
NYNathaniel W. York
Nathaniel W. York
CNColin G. Nichols
Colin G. Nichols
MRMaria S. Remedi
Maria S. Remedi

2 November 2017 in Autophagy
Verified
Journal Article
Closed access
HLHaiyan Liu
Haiyan Liu
AJAli Javaheri
Ali Javaheri
RGRebecca J. Godar
Rebecca J. Godar
JMJohn Murphy
John Murphy
XMXiucui Ma
Xiucui Ma
ADAbhinav Diwan
Abhinav Diwan
Obesity-induced diabetes is characterized by hyperglycemia, insulin resistance, and progressive beta cell failure. In islets of mice with obesity-induced diabetes, we observe increased beta cell death and impaired autophagic flux. We hypothesized that intermittent fasting, a clinically sustainable therapeutic strategy, stimulates autophagic flux to ameliorate obesity-induced diabetes. Our data show that despite continued high-fat intake, intermittent fasting restores autophagic flux in islets and improves glucose tolerance by enhancing glucose-stimulated insulin secretion, beta cell survival, and nuclear expression of NEUROG3, a marker of pancreatic regeneration. In contrast, intermittent fasting does not rescue beta-cell death or induce NEUROG3 expression in obese mice with lysosomal dysfunction secondary to deficiency of the lysosomal membrane protein, LAMP2 or haplo-insufficiency of BECN1/Beclin 1, a protein critical for autophagosome formation. Moreover, intermittent fasting is sufficient to provoke beta cell death in nonobese lamp2 null mice, attesting to a critical role for lysosome function in beta cell homeostasis under fasting conditions. Beta cells in intermittently-fasted LAMP2- or BECN1-deficient mice exhibit markers of autophagic failure with accumulation of damaged mitochondria and upregulation of oxidative stress. Thus, intermittent fasting preserves organelle quality via the autophagy-lysosome pathway to enhance beta cell survival and stimulates markers of regeneration in obesity-induced diabetes.

12 September 2016 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
PDF file
MRM. S. Remedi
M. S. Remedi
CEC. Emfinger
C. Emfinger
Recovery of functional β‐cell mass continues to be an ongoing challenge in treating diabetes. Initial work studying β‐cells suggested apoptotic β‐cell death as a main contributor for the loss of β‐cell mass in diabetes. Restoration of β‐cells either by transplant or stimulating proliferation of remaining β‐cells or precursors would then logically be a viable therapeutic option for diabetes. However, recent work has highlighted the inherent β‐cell plasticity and the critical role of loss of β‐cell identity in diabetes, and has suggested that β‐cells fail to maintain a fully differentiated glucose‐responsive and drug‐responsive state, particularly in diabetic individuals with poorly controlled, long‐lasting periods of hyperglycaemia. Understanding the underlying mechanisms of loss of β‐cell identity and conversion in other cell types, as well as how to regain their mature differentiated functional state, is critical to develop novel therapeutic strategies to prevent or reverse these processes. In this review, we discuss the role of plasticity and loss of β‐cell identity in diabetes, the current understanding of mechanisms involved in altering this mature functional β‐cell state and potential progresses to identify novel therapeutic targets providing better opportunities for slowing or preventing diabetes progression.

19 August 2006 in Diabetologia
Verified
Journal Article
Closed access
PDF file
MRM. S. Remedi
M. S. Remedi
JRJ. V. Rocheleau
J. V. Rocheleau
ATA. Tong
A. Tong
BPB. L. Patton
B. L. Patton
MMM. L. McDaniel
M. L. McDaniel
CNC. G. Nichols
C. G. Nichols

1 December 2009 in Cell Metabolism
Verified
Journal Article
Closed access
MRMaria Sara Remedi
Maria Sara Remedi
CNColin G. Nichols
Colin G. Nichols

9 August 2018 in JCI Insight
Verified
Journal Article
Open access
PDF file
YHYan Huang
Yan Huang
CMConor McClenaghan
Conor McClenaghan
THTheresa M. Harter
Theresa M. Harter
KHKristina Hinman
Kristina Hinman
CHCarmen Halabi
Carmen Halabi
CNColin G. Nichols
Colin G. Nichols
Cantu syndrome (CS) is characterized by multiple vascular and cardiac abnormalities including vascular dilation and tortuosity, systemic hypotension, and cardiomegaly. The disorder is caused by gain-of-function (GOF) mutations in genes encoding pore-forming (Kir6.1, KCNJ8 ) and accessory (SUR2, ABCC9 ) ATP-sensitive potassium (K ATP ) channel subunits. However, there is little understanding of the link between molecular dysfunction and the complex pathophysiology observed, and there is no known treatment, in large part due to the lack of appropriate preclinical disease models in which to test therapies. Notably, expression of Kir6.1 and SUR2 does not fully overlap, and the relative contribution of K ATP GOF in various cardiovascular tissues remains to be elucidated. To investigate pathophysiologic mechanisms in CS we have used CRISPR/Cas9 engineering to introduce CS-associated SUR2[A478V] and Kir6.1[V65M] mutations to the equivalent endogenous loci in mice. Mirroring human CS, both of these animals exhibit low systemic blood pressure and dilated, compliant blood vessels, as well dramatic cardiac enlargement, the effects being more severe in V65M animals than in A478V animals. In both animals, whole-cell patch-clamp recordings reveal enhanced basal K ATP conductance in vascular smooth muscle, explaining vasodilation and lower blood pressure, and demonstrating a cardinal role for smooth muscle K ATP dysfunction in CS etiology. Echocardiography confirms in situ cardiac enlargement and increased cardiac output in both animals. Patch-clamp recordings reveal reduced ATP sensitivity of ventricular myocyte K ATP channels in A478V, but normal ATP sensitivity in V65M, suggesting that cardiac remodeling occurs secondary to K ATP overactivity outside of the heart. These SUR2[A478V] and Kir6.1[V65M] animals thus reiterate the key cardiovascular features seen in human CS. They establish the molecular basis of the pathophysiological consequences of reduced smooth muscle excitability resulting from SUR2/Kir6.1–dependent K ATP GOF, and provide a validated animal model in which to examine potential therapeutic approaches to treating CS.